Monday, April 15, 2024
Home Tags Therapeutics

Tag: Therapeutics

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Invest… –...

0
NEW YORK, Aug. 21, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of...

ALDX Stock News: Shareholders with Significant Losses in Aldeyra Therapeutics, I…...

0
SAN DIEGO, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of...

Indaptus Therapeutics Announces Opening of Next Cohort in Single Dose Ranging...

0
Cohort 1 patients exhibited a significant immune response consistent with the mechanism of actionSafety Review Committee approved continuation to the next cohort of...

BioXcel Therapeutics, Inc. Deadline Approaching: Kessler Topaz Meltzer & Check,…...

0
RADNOR, Pa., Aug. 8, 2023 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class...

Aldeyra Therapeutics, Inc. (ALDX) Shareholder Notice: Robbins LLP Reminds Shareh… –...

0
SAN DIEGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of...

ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages BioXcel Therapeutics, Inc. Inv…...

0
NEW YORK, July 28, 2023 /PRNewswire/ --WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioXcel Therapeutics,...

Cessation Therapeutics Announces Food and Drug Administration Authorization for … –...

0
Company expects to initiate trial in August of 2023 CSX-1004 is being developed for prevention of fentanyl overdose, which claimed more than 74,000...

Aquestive Therapeutics to Report Second Quarter 2023 Financial Results and Recen…...

0
WARREN, N.J., July 25, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. AQST, (the "Company" or "Aquestive"), a pharmaceutical company advancing medicines...

BTAI INVESTOR ALERT: Kaplan Fox & Kilsheimer LLP Notifies BioXcel Therapeutics,...

0
NEW YORK, July 22, 2023 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP reminds investors that a complaint has been filed...

ENB Therapeutics Presents Top-line Results from Phase 1b ENBOLDEN-101 Study in...

0
ENB is developing first in class small molecule ENB-003 to selectively targeting the ETB receptor - a novel immune checkpoint  The ENB-003 in combination...

Press Realease

Business News

Cricket

Weather News

Lifestyle

World News

UK / USA News

Local News